- Video Center
- Social Media
- Media Contacts
Monheim, September 10, 2019 – Bayer announced today that its latest fungicide innovation marketed under the iblon™ technology brand has received first registration worldwide from the New Zealand Ministry for Primary Industries. iblon™ technology is based on the active ingredient isoflucypram, a member of a new subclass in the family of the highly valued SDHIs. It provides excellent disease control resulting in healthy-looking crops that deliver consistently higher yields compared to currently available market standards. The product will be available in New Zealand for the 2019/2020 cereal growing season. Further product launches for iblon™ technology fungicides are expected in other important cereal producing countries once regulatory approval has been completed.
Cereal farmers need innovative and tailored solutions to tackle their daily challenges like limited natural resources, volatile commodity prices and climatic change while feeding a growing world population with high-quality cereals. “The world cereal market requires higher grain quality and production. In addition to the pressure of climatic hazards such as drought, fungal diseases can cause significant yield losses and quality reductions,” said Hartmut van Lengerich, global Head of Crop Protection Asset Management at Bayer. “We’re excited that our newly-registered iblon™ technology will provide cereal growers in New Zealand with a new and powerful tool to sustainably support increased cereal production”
Isoflucypram has an outstanding and long-lasting efficacy against major economically important fungal diseases: Field trials showed excellent efficacy against major leaf diseases such as leaf blotch, net blotch, yellow rust, and brown rust. The outstanding disease control results in an extended period of green leaf retention, setting the crop up for maximum yield potential.
“Bayer’s position as a leading innovator in agriculture has given us the unique opportunity to offer cereal growers in New Zealand the best-in-class SDHI fungicide,” explained Neil Waddingham, Customer Marketing Manager at Bayer New Zealand. “We are very proud of our new iblon™ technology. Products powered by iblon™ technology have delivered increased yield compared to competitor standards in field trials conducted under New Zealand conditions. In the 2018/19 season the average yield increase in wheat was 0.5 t/ha and in barley 0.25 t/ha. It empowers our customers to be more efficient and sustainable at all levels of their business.”
Isoflucypram offers cereal growers long lasting protection against fungal activity, allowing for a prolonged grain-filling period. It is expected that further products powered by iblon™ technology will be released in the future, providing New Zealand farmers with even further opportunities to optimize their farm production. iblon™ technology delivers all of these benefits at low application rates in wheat, barley, triticale and ryegrass; more information on operator and environmental protection, diseases controlled, and application timing is included in the product label.
iblon™ is a Trademark of the Bayer Group.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center